Abstract:Employing assays approved by the U.S. Food and Drug Administration (FDA) to assist in detection of brain injury in mild traumatic brain injury (TBI) patients, this study demonstrated that the astroglial protein, glial fibrillary acidic protein (GFAP) and the neuronal protein, ubiquitin C-terminal hydrolase (UCH-L1) were positively associated with age in COVID-19 patients. Controlling for age, UCH-L1 and GFAP were significantly elevated in COVID-19 patients compared to non-COVID-19 controls, and UCH-L1, but not GFAP, was elevated in patients with neurological alterations. Data from this study are also compared to historical data on levels of UCH-L1 and GFAP in brain injured and healthy normal patients. These data support further studies of an FDA approved assay format that could facilitate timely development, validation, and FDA approval of blood tests to detect neuronal and glial cell injuries following infection by SARS-CoV-2. Moreover, appropriately validated blood tests could detect brain injury originating from any systemic pathogen.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a reliable method to detect markers of neuronal and glial cell damage in the blood of COVID - 19 patients. Specifically, the researchers used a detection platform approved by the US Food and Drug Administration (FDA), aiming to detect the levels of ubiquitin carboxy - terminal hydrolase L1 (UCH - L1), a marker of neuronal damage, and glial fibrillary acidic protein (GFAP), a marker of glial cell damage, in the blood of COVID - 19 patients. By comparing the levels of these markers between COVID - 19 patients and non - COVID - 19 control groups, the researchers hope to verify whether these markers can be used as diagnostic tools for timely detection of brain damage caused by SARS - CoV - 2 infection, and further explore the changes of these markers at different time points and their relationship with neurological symptoms. The main objectives of the study include: 1. **Verify the effectiveness of UCH - L1 and GFAP as markers of brain damage in COVID - 19 patients**: Evaluate the differences in the levels of these two markers by comparing serum samples from COVID - 19 patients and non - COVID - 19 control groups. 2. **Explore the relationship between UCH - L1 and GFAP levels and age, gender, and neurological symptoms**: Analyze whether the levels of these markers are affected by factors such as age and gender, and their performance in patients with neurological symptoms. 3. **Evaluate the changes of these markers at different time points**: Through longitudinal data collection, observe the changing trends of UCH - L1 and GFAP levels during the course of COVID - 19. 4. **Provide a basis for future research**: Through preliminary data analysis, provide references for more in - depth follow - up research, especially regarding the potential of these markers in clinical applications. In summary, this study aims to provide a reliable diagnostic tool for brain damage in COVID - 19 patients by using an FDA - approved detection platform, thereby improving patient management and treatment.

An FDA-approved assay platform can detect biomarkers of neuronal and glial injury in the blood of COVID-19 patients